A conversation with Laurie Glimcher
As Laurie Glimcher was preparing to take over as dean of Weill Cornell Medical College in New York City, SciBX caught up with her to discuss her views on research priorities for academic medical centers, the role of industry-university partnerships in promoting translational research and the potential of New York City to emerge as a biopharma hub. According to Glimcher, there is no one-size-fits-all approach to public-private partnerships, and a combination of models may be most effective.
Previously, Glimcher was a professor at Harvard Medical School and the Harvard School of Public Health and a practicing rheumatologist at Brigham and Women's Hospital. Her research interests span immunology, skeletal biology and neurodegenerative diseases.
At Harvard, Glimcher had multiple interactions with biopharma, including a three-year collaboration with Merck & Co. Inc. that finished late last year. She also is the longest serving director on the board of Bristol-Myers Squibb Co.
SciBX: As you take over as dean of Weill Cornell, how do you plan to boost the translational profile of the college?
Laurie Glimcher: One critical piece will be increasing the school's academic strength through